Core Viewpoint - The company reported a slight decline in revenue and net profit for the reporting period, but showed significant improvement in cash flow from operating activities, indicating a potential for recovery and growth in the future [6]. Financial Performance - The company achieved operating revenue of 3,369.38 million yuan, a year-on-year decrease of 0.43% [6]. - The net profit attributable to shareholders was 690.93 million yuan, down 0.91% year-on-year [6]. - The net profit after deducting non-recurring gains and losses was 662.20 million yuan, reflecting a year-on-year increase of 2.33% [6]. - The net cash flow from operating activities was 636.36 million yuan, showing a substantial year-on-year increase of 300.52% [6]. - Total assets at the end of the reporting period were 25,358.93 million yuan, an increase of 3.20% from the beginning of the period [6]. - The net assets attributable to shareholders were 15,796.89 million yuan, up 3.92% from the beginning of the period [6]. - The weighted average return on net assets was 4.43% [6]. Business Segments Medical Devices - The medical device segment generated the highest revenue, totaling 1,776.47 million yuan, with a year-on-year growth of 1.30% [7]. - The cardiovascular interventional business achieved revenue of 1,238.60 million yuan, a year-on-year increase of 7.57%, with coronary intervention contributing 881.23 million yuan (up 3.60%) and structural heart disease generating 328.71 million yuan (up 32.06%) [7]. - The surgical anesthesia business reported revenue of 241.01 million yuan, down 10.29% year-on-year [8]. - The in-vitro diagnostics business had revenue of 163.37 million yuan, a year-on-year decline of 17.35% [9]. Pharmaceuticals - The pharmaceutical segment reported revenue of 1,117.44 million yuan, a year-on-year decrease of 1.52% but a quarter-on-quarter increase of 79.34% [10]. - The retail channel inventory clearance is nearly complete, with a gradual increase in the revenue share of non-atorvastatin calcium and clopidogrel [10]. - The generic drug segment achieved revenue of 975.35 million yuan, up 3.89% year-on-year, while the raw materials segment saw revenue of 142.10 million yuan, down 27.44% year-on-year [10]. Medical Services and Health Management - The medical services and health management segment generated revenue of 475.47 million yuan, a year-on-year decrease of 4.05% [11]. - The company provides cardiovascular disease medical services and health management through specialized hospitals and e-commerce platforms [11]. - The Hefei Cardiovascular Hospital reported revenue of 83.44 million yuan, an increase of 3.51% year-on-year [11]. - The AI-based health management services, focusing on cardiac monitoring and rehabilitation, generated revenue of 284.38 million yuan, reflecting a year-on-year growth of 8.64% [11].

证券之星消息，截至2025年8月22日收盘，赛诺医疗(688108)报收于32.7元，下跌4.44%，换手率 14.54%，成交量60.51万手，成交额20.1亿元。 8月22日的资金流向数据方面，主力资金净流出2.09亿元，占总成交额10.4%，游资资金净流入1.35亿 元，占总成交额6.72%，散户资金净流入7390.73万元，占总成交额3.68%。 | 日期 | 涨跌幅 | 融资余额(元) | 融资净买入(元) 融券余量(股) | | 融券净卖出(股) | 融资融券余额(元) | | --- | --- | --- | --- | --- | --- | --- | | 2025-08-22 | -4.44% | 265.6 | -1269.64万 | 0.0 | 0.0 | 9.39亿 | | 2025-08-21 | -8.21% | 9.51亿 | 1938.34万 | 0.0 | -200.0 | 9.51亿 | | 2025-08-20 | -7.77% | 9.32亿 | -2651.39万 | 200.0 | 0.0 | 9.32亿 | | 2025-08-19 | -2.56% | 9. ...

融券方面，当日融券卖出0.00万股，净卖出0.00万股。 来源：金融界 最近三个交易日，20日-22日，迈得医疗分别获融资买入0.03亿元、0.08亿元、0.16亿元。 8月22日，沪深两融数据显示，迈得医疗获融资买入额0.16亿元，居两市第1250位，当日融资偿还额0.11 亿元，净买入438.98万元。 ...

最近三个交易日，20日-22日，春立医疗分别获融资买入0.13亿元、0.07亿元、0.15亿元。 融券方面，当日融券卖出0.00万股，净卖出0.00万股。 8月22日，沪深两融数据显示，春立医疗获融资买入额0.15亿元，居两市第1288位，当日融资偿还额0.16 亿元，净卖出89.17万元。 来源：金融界 ...

融券方面，当日融券卖出0.30万股，净买入0.43万股。 来源：金融界 8月22日，沪深两融数据显示，联影医疗获融资买入额1.03亿元，居两市第309位，当日融资偿还额1.05 亿元，净卖出110.95万元。 最近三个交易日，20日-22日，联影医疗分别获融资买入0.85亿元、1.03亿元、1.03亿元。 ...

融券方面，当日融券卖出0.00万股，净买入0.02万股。 来源：金融界 8月22日，沪深两融数据显示，心脉医疗获融资买入额0.29亿元，居两市第893位，当日融资偿还额0.27 亿元，净买入227.70万元。 最近三个交易日，20日-22日，心脉医疗分别获融资买入0.44亿元、0.29亿元、0.29亿元。 ...

来源：金融界 最近三个交易日，20日-22日，赛诺医疗分别获融资买入3.78亿元、3.31亿元、3.16亿元。 融券方面，当日融券卖出0.00万股，净卖出0.00万股。 8月22日，沪深两融数据显示，赛诺医疗获融资买入额3.16亿元，居两市第70位，当日融资偿还额3.29亿 元，净卖出1269.64万元。 ...

融券方面，当日融券卖出0.00万股，净卖出0.00万股。 来源：金融界 最近三个交易日，20日-22日，伟思医疗分别获融资买入0.36亿元、0.22亿元、0.15亿元。 8月22日，沪深两融数据显示，伟思医疗获融资买入额0.15亿元，居两市第1279位，当日融资偿还额0.22 亿元，净卖出649.73万元。 ...

8月22日，沪深两融数据显示，奥精医疗获融资买入额0.12亿元，居两市第1432位，当日融资偿还额0.12 亿元，净卖出79.86万元。 最近三个交易日，20日-22日，奥精医疗分别获融资买入0.11亿元、0.10亿元、0.12亿元。 融券方面，当日融券卖出0.00万股，净卖出0.00万股。 来源：金融界 ...

养老金视角，本期较上一期持股增加的养老金基金共计1个，即基本养老保险基金八零二组合，持股增 加占比达0.2%。。本期较上一季度新披露的养老金基金共计1个，即基本养老保险基金一二零一组合。 外资态度来看，本期较上一季度持股减少的外资基金共计1个，即香港中央结算有限公司，持股减少占 比达0.69%。 2025年8月23日，鱼跃医疗(002223.SZ)发布2025年半年度报告。截至2025年8月22日，共有76个机构投 资者披露持有鱼跃医疗A股股份，合计持股量达3.77亿股，占鱼跃医疗总股本的37.60%。其中，前十大 机构投资者包括江苏鱼跃科技发展有限公司、中国银行股份有限公司-华宝中证医疗交易型开放式指数 证券投资基金、香港中央结算有限公司、全国社保基金一零二组合、全国社保基金一一三组合、基本养 老保险基金八零二组合、中国农业银行股份有限公司-中证500交易型开放式指数证券投资基金、基本养 老保险基金一二零一组合、博时成长领航混合A、大成企业能力驱动混合A，前十大机构投资者合计持 股比例达34.76%。相较于上一季度，前十大机构持股比例合计下跌了0.73个百分点。 公募基金方面，本期较上一期持股增加的公募基金 ...